Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation

Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation

<p><strong>Background</strong></p> <p>The TWO Study (Transplantation Without Overimmunosuppression) aimed to investigate a novel approach to regulatory T-cell (Treg) therapy in renal transplant patients, using a delayed infusion protocol at 6 mo posttransplant to promot...

Podrobná bibliografie
Hlavní autoři:	Brook, MO, Hennessy, C, Hester, J, Hammad, S, Alzhrani, A, Rombach, I, Dutton, S, Lombardi, G, Wood, KJ, Friend, P, Harden, PN, Issa, F
Médium:	Journal article
Jazyk:	English
Vydáno:	Wolters Kluwer 2024

Podobné jednotky

Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients
Autor: Brook, MO, a další
Vydáno: (2022)

Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients
Autor: Susan Dutton, a další
Vydáno: (2022-04-01)

Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy.
Autor: Hester, J, a další
Vydáno: (2011)

Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
Autor: Muthusamy, A, a další
Vydáno: (2008)

Steroid-free immunosuppression in pancreas transplantation using Alemtuzumab induction
Autor: Muthusamy, A, a další
Vydáno: (2007)

Alemtuzumab: right drug, right dose?
Autor: Haynes, R, a další
Vydáno: (2011)

Feasibility, long‐term safety and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients
Autor: Harden, PN, a další
Vydáno: (2020)

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
Autor: Flechner, S, a další
Vydáno: (2005)

Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.
Autor: Plata-Munoz, J, a další
Vydáno: (2009)

Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
Autor: Trzonkowski, P, a další
Vydáno: (2008)

ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
Autor: Muthusamy, A, a další
Vydáno: (2011)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
Autor: Haynes, R, a další
Vydáno: (2014)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
Autor: Haynes, R, a další
Vydáno: (2014)

Chimeric antigen receptors and regulatory T cells: the potential for HLA-specific immunosuppression in transplantation
Autor: Wright, S, a další
Vydáno: (2021)

Dampened inflammatory signalling and myeloid-derived suppressor-like cell accumulation reduces circulating monocytic HLA-DR density and may associate with malignancy risk in long-term renal transplant recipients
Autor: Bottomley, MJ, a další
Vydáno: (2022)

Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
Autor: Sutherland, A, a další
Vydáno: (2014)

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation
Autor: Sabrina Wright, a další
Vydáno: (2022-03-01)

B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naive B cells.
Autor: Heidt, S, a další
Vydáno: (2012)

B cell repopulation after alemtuzumab induction - Transient increase in transitional B cells and long-term dominance of naïve B cells
Autor: Heidt, S, a další
Vydáno: (2012)

Alemtuzumab induction and steroid free immunosupprssion in pancreas transplantation.
Autor: Muthusamy, A, a další
Vydáno: (2007)

Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients
Autor: Martina Guthoff, a další
Vydáno: (2020-05-01)

Regulatory cell therapy in kidney transplantation (The ONE Study): A harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
Autor: Sawitzki, B, a další
Vydáno: (2020)

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates
Autor: Ana Rita da Fonseca, a další
Vydáno: (2025-02-01)

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES
Autor: AR Fonseca, a další
Vydáno: (2023-10-01)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Autor: Haynes, R, a další
Vydáno: (2014)

Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients
Autor: Milena Elimelakh, a další
Vydáno: (2007-08-01)

Expanded criteria donors in pancreas transplantation: The Oxford experience
Autor: Muthusamy, A, a další
Vydáno: (2009)

Alemtuzumab in the up-front setting
Autor: Matthew Kaufman, a další
Vydáno: (2008-04-01)

Alemtuzumab in the treatment of multiple sclerosis
Autor: Fernandez Ó
Vydáno: (2014-02-01)

Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment
Autor: Ema Kantorová, a další
Vydáno: (2024-10-01)

Donors With Previous Malignancy: When Is It Safe to Proceed With Organ Transplantation?
Autor: Vitor Turra, a další
Vydáno: (2025-01-01)

Alemtuzumab induction combined with reduced maintenance immunosuppression is associated with improved outcomes after lung transplantation: A single centre experience.
Autor: Alberto Benazzo, a další
Vydáno: (2019-01-01)

Systematic reviews of alemtuzumab in renal transplantation.
Autor: O'Callaghan, J, a další
Vydáno: (2013)

Systematic reviews of alemtuzumab in renal transplantation
Autor: O'Callaghan, J, a další
Vydáno: (2013)

Alemtuzumab in treatment of chronic lymphocytic leukemia
Autor: S. S. Bessmeltsev, a další
Vydáno: (2022-11-01)

Typhlitis as a complication of alemtuzumab therapy
Autor: I. Marie, a další
Vydáno: (2007-05-01)

Inclusion Body Myositis Treated with Alemtuzumab
Autor: Juliana Sá, a další
Vydáno: (2019-12-01)

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.
Autor: Innes, A, a další
Vydáno: (2013)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
Autor: Watson, C, a další
Vydáno: (2004)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
Autor: Havrdova E, a další
Vydáno: (2017-10-01)